Trial Profile
Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical Approaches
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Lapatinib (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 May 2018 Primary endpoint (Overall Response Rate) has been met, according to the results published in the Cancer
- 09 May 2018 Results published in the Cancer
- 21 Mar 2018 Planned End Date changed from 1 Aug 2019 to 1 Nov 2031.